Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Phase 1 Open-Label Two-Way Cross Over Study to Assess the Pharmacokinetic Profile of Two Formulations of PB1023 Injection Following a Single Dose Administered By Subcutaneous Injection in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01427257
• Other study ID #: PB1023-PT-CL-0002
• Status: Completed
• Phase: Phase 1
• First received: August 29, 2011
• Last updated: September 28, 2012
• Start date: February 2012
• Est. completion date: September 2012

Study information

• Verified date: September 2012
• Source: PhaseBio Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Primary objective:

To compare the pharmacokinetic profile of PB1023 after a single dose administered by subcutaneous injection of two formulations (concentrations).

Secondary objectives:

To evaluate the safety and tolerability of two formulations of PB1023 Injection administered as a subcutaneous injection in adult subjects with T2DM.

To evaluate the impact on the pharmacokinetic profile of PB1023 after a single 90 mg dose of formulation B (100 mg/mL) administered cold at 2 to 8°C by subcutaneous injection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Willing and able to sign a written informed consent and follow all study related procedures.

• Males or post menopausal or surgically sterile females age 18 - 75 years of age inclusive.

• Diagnosed with T2DM for = 6 months.

• HbA1c of = 6.0% if diet and exercise controlled, or =5.8% if taking one or more glucose lowering agents

• Weight = 45 kg and BMI = 40 kg/m2

• In otherwise stable health except for T2DM (no clinically significant laboratory abnormalities, vital signs, ECG findings or clinically significant underlying disease that would put the subject at risk for participation in the study).

• Receiving stable doses of concomitant medications for 30 days prior to dosing.

• Criteria for Participation in Period 3 only: Received PB1023 Injection at 50 mg/mL and 100 mg/mL during Period 1 or 2 of the study and had adequate pharmacokinetic samples collected for evaluation of their pharmacokinetic profile.

Exclusion Criteria:

• Currently taking Byetta® or Victoza®.

• Previously received PB1023 Injection other than under this study protocol.

• Known allergy or serious adverse effect to an approved or investigational GLP-1 receptor analog/agonist.

• Unstable cardiovascular disease defined as:

• History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to the Screening visit.

• Screening (duplicate supine reading) BP = 160 mmHg (systolic) or = 100 mmHg (diastolic).

• Mean triplicate 12-lead ECG demonstrating QT interval (corrected) (QTc) > 450 msec in males and > 470 msec in females at the Screening visit, or a history or evidence of long QT syndrome.

• Based on contraindications/warnings identified with other GLP-1 receptor agonists, subjects will be excluded if they have:

• History, symptoms or signs of pancreatitis or severe gastrointestinal disease (i.e., gastroparesis)

• Personal or family history of medullary thyroid tumors or history of Multiple Endocrine Neoplasia Syndrome Type 2. Note: Abnormal serum calcitonin at screening will exclude the subject from participation.

• Clinically significant renal and/or hepatic dysfunction at screening as indicated by the following:

• eGFR as calculated by MDRD of < 60 mL/min

• Urine dipstick protein > 2+ (100 mg/dL) or urine protein 2+ and a Urine Protein/Creatinine ratio > 1.0 (> 1000 mg/g)

• Alanine aminotransferase (ALT) > 2 x ULN

• Aspartate aminotransferase (AST) > 2 x ULN

• Serum bilirubin = 1.6 mg/dL

• Pregnant or lactating females

• Known history of or active alcohol or drug abuse within 12 months prior to Screening or positive alcohol and/or drug screen.

• Positive for Human Immunodeficiency Virus (HIV) antibodies, Hepatitis B surface antigen (HBsAg) or Hepatitis C Virus (HCV) antibodies.

• Participating in any other study and have received any other investigational drug or device within 30 days prior to the Screening visit or are taking part in a non-drug study which in the opinion of the Investigator would interfere with the outcome of the study.

• Other medical (i.e., acute or chronic illness) or psychiatric condition which in the opinion of the Investigator would place the subject at increased risk, confound the primary study endpoint, or would preclude obtaining voluntary consent.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• Single Dose PB1023
Single Dose PB1023 Formulation A
• Single Dose PB1023
Single Dose PB1023 Formulation B
• Single Dose PB1023
Single Dose PB1023 Formulation B

Locations

Country	Name	City	State
United States	Prism Research	Saint Paul	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
PhaseBio Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics	The pharmacokinetic profile of two formulations of PB1023 will be compared. The following parameters will be evaluated: t1/2, AUC(inf), AUC(0-t), Tmax, Cmax, Elimination Rate Constant, Clearance and Distribution.	For each dosing period: Pre-dose, 1, 4, 8, 12 hours, 1, 2, 3, 4, 7 and 10 days post-dose	No
Secondary	Safety/Tolerability	Safety will be evaluated by analyses of incidence of adverse events of interest (possibly related to the class of drug) and other adverse events. Vital signs, ECGs and safety laboratory parameters will also be presented.	42 Days	Yes